Targeting SLC7A11/xCT improves radiofrequency ablation efficacy of HCC by dendritic cells mediated anti‐tumor immune response

Targeting SLC7A11/xCT improves radiofrequency ablation efficacy of HCC by dendritic cells mediated anti‐tumor immune response

After RFA treatment in patients with liver cancer, the expression of SLC7A11/xCT and the proportion of DCs in the TME were significantly increased. SLC7A11/xCT is a poor prognostic marker for liver cancer and is mainly expressed in DCs in the TME. Targeting xCT in DCs combined with RFA significantly...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:iMeta 2024-12, Vol.3 (6), p.e248-n/a
Hauptverfasser: Jin, Yuzhao, Cai, Songhua, Zhou, Yang, Guo, Dandan, Zeng, Yuzhen, Xu, Wangting, Sun, Yiting, Shi, Yueli, Xu, Zhiyong, Liu, Zaoqu, Luo, Peng, Huang, Zhao, Tang, Bufu
Format: Artikel
Sprache:eng
Schlagworte:
Correspondence
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:After RFA treatment in patients with liver cancer, the expression of SLC7A11/xCT and the proportion of DCs in the TME were significantly increased. SLC7A11/xCT is a poor prognostic marker for liver cancer and is mainly expressed in DCs in the TME. Targeting xCT in DCs combined with RFA significantly enhances anti‐tumor immunity, suppressing tumor growth and offering a promising strategy for improved therapeutic outcomes in liver cancer.
ISSN:2770-596X
2770-5986
2770-596X
DOI:10.1002/imt2.248